CoChat

Systematic review with meta‐analysis: highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation

Shin, A., Camilleri, M., Kolar, G., Erwin, P., West, C. P., Murad, M. H. · 2014 · Alimentary Pharmacology & Therapeutics
Cited by 145

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Summary: Background: Highly selective 5‐HT4 agonists have been suggested for the treatment of chronic constipation (CC). Aim: To assess the effects of highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) on patient‐important clinical efficacy outcomes and safety in adults with CC. Methods: We searched the medical literature in January 2013 using MEDLINE/Pubmed, Embase, Cochrane Library, and Web of Science/Scopus for randomised, controlled trials of highly selective 5‐HT4 agonists in adults with CC, with no minimum duration of therapy (maximum 12 weeks) or date limitations. Data were extracted from intention‐to‐treat analyses, pooled using a random‐effects model, and reported as relative risk (RR), mean differences, or standardised mean differences with 95% confidence intervals (CI). Results: Main outcomes included stool frequency, Patient‐Assessment of Constipation Quality of Life (PAC‐QOL),PAC of symptoms (PAC‐SYM) and adverse events. Thirteen eligible trials were identified: 11 prucalopride, 1 velusetrag, 1 naronapride. Relative to control, treatment with highly selective 5‐HT4 agonists was superior for all outcomes: mean ≥3 spontaneous complete bowel movements (SCBM)/week (RR = 1.85; 95%CI 1.23–2.79); mean ≥1 SCBM over baseline (RR = 1.57; 95%CI 1.19, 2.06); ≥1 point improvement in PAC‐QOL and PAC‐SYM scores. The only active comparator trial of prucalopride and PEG 3350 suggested PEG 3350 is more efficacious for some end points. Adverse events were more common with highly selective 5‐HT4 agonists, but were generally minor; headache was the most frequent. Most trials studied prucalopride. Conclusion: Demonstration of efficacy on patient‐important outcomes and a favourable safety profile support the continued use and development of highly selective 5–HT4 agonists in the treatment of chronic constipation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.12571

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 145

Metadata

Authors
Shin, A., Camilleri, M., Kolar, G., Erwin, P., West, C. P., & Murad, M. H.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2013-12-05
Volume
39
Issue
3
Pages
239-253
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1977235441
Cited by
145
References
8
FWCI
2.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.